Ra Capital Management, L.P. bought $1.7M of Hemab Therapeutics (COAG)

Executed Jun 15, disclosed Jun 17, 2 days later.

Value, as filed

$1.7M

67,669 sh across 2 lots

Executed

Jun 15

the trade date, as filed

Disclosed

Jun 17

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+88.1%

+72.5% from execution

Over the 21 trading sessions from the disclosed entry session (Jun 17), the stock returned +88.1% (delay-adjusted); from the execution session (Jun 15), +72.5%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

RP Ra Capital Management, L.P. Director profile →

Ra Capital Management, L.P. (Director) filed 31 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 22 priced purchase filings, the average 21-session return was +16.2% from execution and +14.2% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.

The name

COAG

Hemab Therapeutics Holdings, Inc. COAG · Healthcare · 4 filings in 24 months ticker →

Healthcare · Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of b…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Ra Capital Management, L.P. in COAG

COAGPURCHASE Hemab Therapeutics Holdings, Inc. $159K
6,387 sh × $24.90
Exec May 12
Filed May 14 · 5:21 PM ET COAGPURCHASE Hemab Therapeutics Holdings, Inc. $1.2M
47,790 sh across 3 lots
Exec May 7
Filed May 11 · 5:44 PM ET COAGPURCHASE Hemab Therapeutics Holdings, Inc. $52.2M
2,840,429 sh across 6 lots
Exec May 4
Filed May 6 · 7:16 PM ET